Skip to main content
TipRanks
Go Ultimate75% OFF

Conmed (CNMD) AI Stock Analysis

210 Followers
CNMD

Conmed

(NYSE:CNMD)

Select Model
Rating:62Neutral
Price Target:$54.00â–²(9.42% Upside)
Action:reiterated
Date:10/29/26

The score is driven primarily by stable-but-not-robust financial performance: improving margins and leverage are offset by sharp TTM revenue decline and weakening cash-flow trend. The latest earnings call was supportive (maintained organic growth outlook and raised EPS guidance), while technicals are mixed with neutral momentum. Valuation is reasonable (mid-teens P/E) but the dividend yield is minimal.

Positive Factors
Organic GrowthOrganic growth across both major product lines indicates broadening demand rather than reliance on a single franchise. This supports revenue durability, improves operating leverage, and gives ConMed a stronger base for continued expansion over the next several quarters.
Negative Factors
Revenue ContractionThe sharp TTM revenue decline signals weaker recent demand, volume, or mix and reduces earnings resilience. Although organic growth has improved, the contraction means ConMed must sustain recovery across products and markets before growth can be viewed as dependable.

Conmed (CNMD) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%30%40%CNMD+21.82%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.47B
Dividend Yield
―
Average Volume (3M)
362.48K
Price to Earnings (P/E)
20.5
Beta (1Y)
0.56
Revenue Growth
1.93%
EPS Growth
16.93%
Country
US
Employees
3,900
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Conmed Business Overview & Revenue Model

Company Description

CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfo...

How the Company Makes Money

CONMED makes money primarily by selling medical devices and related surgical products to healthcare providers and distributors, generating revenue when its products are purchased for use in operating rooms and procedural settings. Its core revenue st...

Conmed Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:7.85%|Next Earnings Date:Feb 03, 2027
Earnings Call SentimentPositive

The call was broadly positive. Third-quarter organic revenue growth was 6.7%, both major product lines grew organically, AirSeal, direct Buffalo Filter, and BioBrace performed well, and adjusted EPS exceeded expectations with higher full-year EPS guidance. The main negatives were declining reported revenue and adjusted EPS, lower free cash flow, weaker U.S. orthopedic and OEM smoke-evacuation sales, higher interest expense, tariff exposure, and a narrowed high end of revenue guidance. Overall, the highlights significantly outweighed the lowlights.

Positive Updates

Strong Organic Revenue Growth
Third-quarter net revenue was $335.6 million. Organic constant currency revenue increased 6.7% year over year, consistent with expectations, with balanced contributions from general surgery and orthopedic surgery.

Negative Updates

Reported Revenue Declined
Third-quarter net revenue decreased 70 basis points on an as-reported basis and 80 basis points on a constant currency basis. Organic growth excludes GI product sales following the company's strategic exits from those products.

Company Guidance

For full year 2026, ConMed expects at least 5% organic constant currency revenue growth, with net sales growth of 5% to 5.5%, GI revenue of approximately $20 million, and changes in foreign currency exchange rates representing a tailwind to GAAP results of approximately $9 million; non GAAP adjusted diluted earnings per share are expected in the range of $4.54 to $4.61, adjusted gross margin of approximately 57.5%, adjusted interest expense of approximately $33.7 million, adjusted effective tax rate of approximately 24.5%, free cash flow of approximately $115 million, weighted average shares outstanding of 30.2 million, and $62 million allocated to share repurchase. Fourth-quarter guidance is GAAP net sales of between $364 million and $370 million, organic constant currency growth in the range of 5.1% to 6.8% excluding expected GI revenue of approximately $3.7 million and an FX tailwind of approximately $650 thousand, and adjusted EPS of between $1.23 and $1.30; the company also expects a $0.35 tariff impact ignoring the tariff refunds and 50 to 100 basis points of gross margin expansion with and without the refund.

Conmed Financial Statement Overview

Summary

Profitability and gross margin improved versus 2025 and leverage is trending better (debt-to-equity down to ~0.77 TTM), but near-term fundamentals are pressured by sharply negative TTM revenue growth (~-22%) and deteriorating free-cash-flow momentum despite still-positive FCF (~$133M TTM).

Income Statement

58Neutral

Balance Sheet

64Positive

Cash Flow

51Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.37B1.37B1.31B1.24B1.05B1.01B
Gross Profit783.38M725.38M733.03M676.25M571.25M568.04M
EBITDA211.37M176.49M251.63M172.00M27.56M179.33M
Net Income73.43M47.05M132.42M64.46M-80.58M62.54M
Balance Sheet
Total Assets2.30B2.33B2.31B2.30B2.30B1.77B
Cash, Cash Equivalents and Short-Term Investments47.97M40.82M24.46M24.30M28.94M20.85M
Total Debt815.87M834.94M905.78M991.25M1.05B684.66M
Total Liabilities1.24B1.29B1.34B1.47B1.55B980.58M
Stockholders Equity1.06B1.03B962.68M834.22M745.54M785.43M
Cash Flow
Free Cash Flow132.69M150.88M153.88M106.32M11.58M96.90M
Operating Cash Flow146.31M170.69M166.97M125.35M33.37M111.77M
Investing Cash Flow6.69M-20.96M-13.08M-20.03M-249.53M-14.87M
Financing Cash Flow-143.11M-135.82M-151.00M-110.43M225.00M-101.55M

Conmed Technical Analysis

Technical Analysis SentimentPositive
Last Price49.35

Price Trends

50DMA47.17Positive
100DMA46.09Positive
200DMA41.96Positive

Market Momentum

MACD1.08Negative
RSI52.05Neutral
STOCH42.57Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNMD, the sentiment is Positive. The current price of 49.35 is above the 20-day moving average (MA) of 49.01, above the 50-day MA of 47.17, and above the 200-day MA of 41.96, indicating a bullish trend. The MACD of 1.08 indicates Negative momentum. The RSI at 52.05 is Neutral, neither overbought nor oversold. The STOCH value of 42.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNMD.

Conmed Risk Analysis

Conmed disclosed 37 risk factors in its most recent earnings report. Conmed reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our financial performance is subject to risks in connection with divestitures, and our failure to manage these divestitures could have a negative impact on our business.Q4, 2025
2.Our use of artificial intelligence ("AI") and other emerging technologies could adversely impact our business and financial results.Q4, 2025
3.We are subject to various U.S. federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our reputation, subject us to significant fines and liability or otherwise adversely affect our business.Q4, 2025

Conmed Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CNMD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SYKSYK75Outperform$118.29B32.7415.61%1.13%7.87%22.82%
SNNSNN69Neutral$12.96B20.4012.25%2.56%5.26%31.02%
ZBHZBH69Neutral$19.19B25.656.05%0.95%6.98%-2.22%
CNMDCNMD62Neutral$1.47B20.467.07%―1.93%16.93%
ENOVENOV58Neutral$1.61B-2.98-35.53%―3.28%62.02%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IARTIART40Underperform$1.09B84.361.24%―0.84%―

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%CNMDENOVIARTSNNSYKZBHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CNMD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CNMDConmed Corporation49.357.5117.95%
ENOVEnovis Corporation27.92-0.32-1.13%
IARTIntegra Lifesciences13.982.5622.42%
SNNSmith & Nephew Snats30.97-0.74-2.33%
SYKStryker Corp310.72-44.86-12.62%
ZBHZimmer Biomet Holdings101.4113.2715.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026